signific
progress
made
reduc
risk
pathogen
transmiss
transfus
recipi
nonetheless
remain
continu
risk
transmiss
virus
bacteria
protozoa
prion
recipi
includ
mani
virus
specif
screen
test
exist
well
pathogen
test
current
done
includ
variou
speci
bacteria
babesiosi
variant
creutzfeldjacob
diseas
hepat
viru
human
herp
viru
chikungunya
viru
chaga
diseas
malaria
pathogen
inactiv
pi
technolog
potenti
provid
addit
way
protect
blood
suppli
emerg
agent
also
provid
addit
protect
known
asyetunidentifi
agent
howev
impact
pi
product
qualiti
recipi
safeti
remain
determin
purpos
consensu
confer
bring
togeth
intern
expert
effort
consid
follow
issu
respect
pi
implement
criteria
licens
requir
blood
servic
clinic
issu
risk
manag
issu
costbenefit
impact
research
requir
proceed
provid
make
avail
transfus
medicin
commun
consider
amount
import
inform
present
consensu
confer
c
elsevi
inc
right
reserv
lthough
signific
progress
made
reduc
risk
pathogen
transmiss
transfus
recipi
remain
continu
risk
transmiss
virus
bacteria
protozoa
prion
recipi
includ
virus
specif
screen
test
exist
hepat
b
viru
hbv
hepat
c
viru
hcv
human
tcell
leukotroph
viru
iii
hiv
west
nile
viru
wnv
addit
pathogen
test
current
avail
andor
done
shown
advers
affect
blood
suppli
includ
variou
speci
bacteria
babesiosi
variant
creutzfeldjacob
diseas
vcjd
hepat
viru
hav
human
herp
viru
chikungunya
viru
chaga
diseas
malaria
pathogen
inactiv
pi
technolog
may
provid
addit
way
protect
blood
suppli
emerg
agent
also
provid
addit
protect
known
asyetunidentifi
agent
howev
impact
pi
product
qualiti
safeti
remain
determin
consensu
confer
entitl
pathogen
inactiv
make
decis
new
technolog
base
format
use
previous
initi
propos
us
nation
institut
health
http
consensu
nihgovaboutcdphtm
particip
consensu
confer
consist
distinct
group
intern
expert
summar
avail
data
provid
addit
inform
relat
pi
b
individu
divers
background
form
consensu
panel
respons
write
final
consensu
confer
statement
c
approxim
invit
deleg
particip
activ
discuss
variou
present
specif
question
address
consensu
confer
panel
follow
research
requir
inform
consider
researchrel
question
would
need
answer
decid
whetherwhen
particular
pi
procedur
implement
present
intern
group
expert
provid
background
data
question
summar
articl
discuss
took
place
present
panel
preliminari
report
summar
elsewher
present
harvey
j
alter
md
nation
institut
health
bethesda
md
precautionari
principl
first
endors
us
food
drug
administr
fda
crisi
hiv
contamin
blood
system
state
situat
scientif
uncertainti
possibl
risk
taken
account
even
absenc
proof
contrari
corollari
assert
principl
potenti
seriou
risk
aris
measur
must
taken
minim
risk
could
therefor
argu
pi
blood
product
repres
quintess
precautionari
principl
almost
potenti
transfusiontransmiss
diseas
erad
often
respons
agent
even
recogn
let
alon
conclus
establish
risk
health
recipi
prevent
transfusiontransmit
infect
tradit
accomplish
test
donor
infecti
diseas
marker
approach
certainli
achiev
great
success
reduc
risk
blood
transfus
risk
transfusionacquir
hepat
exampl
reduc
nearli
near
zero
combin
restrict
donor
select
increasingli
sensit
screen
assay
reduct
risk
howev
occur
period
decad
interim
countless
transfus
recipi
harm
hepat
b
viru
exampl
first
recogn
transfus
risk
blood
donor
could
effect
screen
firstgener
assay
histor
australia
antigen
known
hepat
b
surfac
antigen
assay
quickli
refin
combin
adopt
allvolunt
donor
system
reduc
overal
risk
transfusionacquir
hbv
less
nevertheless
transfusionacquir
hepat
caus
continu
occur
incid
approxim
throughout
primarili
diseas
identifi
syndrom
nonanonb
hepat
adopt
surrog
assay
diseas
eg
elev
donor
alanin
aminotransferas
level
exclus
donor
behavior
risk
factor
decreas
volum
blood
transfus
combin
decreas
incid
transfusionacquir
hepat
around
introduct
specif
serolog
assay
recogn
hcv
incid
transfusionassoci
hepat
fell
less
point
howev
much
damag
alreadi
done
one
assum
million
patient
transfus
per
year
unit
state
follow
million
peopl
acquir
transfusionacquir
hepat
case
hcv
diseas
carri
risk
chronic
risk
cirrhosi
lead
etiolog
caus
liver
transplant
north
america
interv
recognit
transfusiontransmiss
diseas
implement
measur
prevent
time
shorten
thu
wherea
took
year
introduc
screen
hbv
year
hcv
year
recognit
hiv
develop
donor
screen
test
wnv
interv
year
yet
continu
except
trend
donor
test
chaga
diseas
first
recommend
blood
product
advisori
committe
us
food
drug
administr
implement
year
later
perhap
importantli
often
earlier
period
delay
diseas
appreci
pose
risk
recipi
blood
transfus
inde
human
health
gener
harm
caus
diseas
call
fix
inevit
properti
transfus
practic
diseas
come
mani
zoonot
origin
transit
signific
human
pathogen
result
primat
virus
enter
food
suppli
africa
eg
hiv
shift
geograph
relationship
diseas
vector
human
serv
incident
host
eg
wnv
larg
safeguard
blood
suppli
hiv
transfusiontransmit
hepat
transfus
medicin
commun
confront
evergrow
list
new
adversari
malaria
dengu
babesiosi
ehrlichiosi
borreliosi
human
herp
viru
trypanosoma
cruzi
chaga
diseas
name
known
pathogen
transmiss
blood
transfus
inde
dengu
fever
may
well
emerg
next
true
threat
blood
suppli
alreadi
caus
approxim
million
case
death
around
world
year
case
dengu
fever
asymptomat
median
viremia
day
viru
mosquito
vector
expand
global
distribut
hand
blood
industri
may
initi
screen
test
dengu
find
confront
complet
unanticip
threat
differ
pathogen
dilemma
face
therefor
whether
wait
see
pathogen
emerg
seriou
risk
blood
suppli
take
action
case
inevit
consign
thousand
perhap
million
patient
infecti
harm
interim
simpli
start
test
donor
potenti
transmiss
pathogen
would
prohibit
expens
face
stark
choic
pi
technolog
attract
third
option
moreov
alreadi
proven
valu
transfusiontransmit
wnv
exampl
infect
peopl
unit
state
includ
neurolog
diseas
implement
donor
screen
assay
estim
patient
experienc
subclin
diseas
none
infect
howev
occur
via
fraction
plasma
product
prior
implement
solventdeterg
sd
method
pi
plasma
fraction
industri
sober
contempl
much
harm
could
avoid
addit
safeti
measur
implement
earli
hemophilia
commun
begin
ravag
hiv
hcv
although
sd
treatment
applic
cellular
blood
product
rbc
platelet
concentr
process
target
nucleic
acid
eg
amotosalen
riboflavin
avail
addit
block
transmiss
known
unknown
pathogen
includ
virus
bacteria
spirochet
protozoa
pi
may
also
prevent
transfusionassoci
graftvshost
diseas
gvhd
disabl
donor
lymphocyt
concern
thu
far
prevent
widespread
adopt
pi
technolog
exagger
although
pi
invari
involv
addit
novel
chemic
substanc
blood
product
substanc
either
benign
eg
riboflavin
subsequ
remov
residu
level
far
establish
toxic
threshold
eg
amotosalen
treat
platelet
toxic
residu
amustalin
treat
rbc
requir
investig
reduct
product
yield
pi
necessit
gener
modest
consist
accept
product
modif
cell
wash
leukoreduct
addit
cost
pi
consider
potenti
save
may
subsequ
realiz
via
elimin
exist
donor
screen
assay
eg
chaga
diseas
product
test
eg
bacteri
test
platelet
product
modif
ie
irradi
futur
cost
new
screen
assay
could
also
avoid
could
grow
cost
otherwis
inexor
progress
minipool
singleunit
nucleic
acid
test
nat
final
addit
layer
safeti
offer
pi
might
allow
blood
collect
agenc
loosen
donor
exclus
criteria
eg
geograph
exclus
malaria
therebi
increas
size
avail
blood
suppli
case
implement
nat
close
collabor
blood
banker
government
regul
privat
sector
requir
make
univers
pi
blood
product
realiti
goal
practic
multicompon
system
maxim
safeti
maintain
adequ
product
yield
accept
toxic
accomplish
reason
period
requir
addit
government
fund
improv
exist
technolog
develop
new
process
particularli
regard
pi
rbc
howev
must
make
perfect
enemi
good
ideal
multicompon
system
realiti
exist
pathogen
reduct
technolog
implement
platelet
transfus
plasma
approach
alreadi
undertaken
mani
part
europ
take
next
step
north
america
requir
invest
resourc
polit
willpow
perhap
importantli
chang
collect
mindset
regard
notion
accept
risk
pathogen
blood
compon
may
intracellular
extracellular
techniqu
inactiv
remov
incur
signific
biolog
chemic
alter
upon
therapeut
product
success
thu
predic
exist
specif
target
pathogen
absent
irrelev
compon
function
current
pi
techniqu
either
target
membran
nucleic
acid
tabl
meant
go
beyond
histor
success
plasma
plasma
deriv
pi
cohn
fraction
heat
treatment
membran
envelopedisrupt
method
organ
solvent
deterg
thu
remain
applic
acellular
compon
use
method
limit
inabl
disarm
class
nonenvelop
virus
method
generaliz
potenti
spectrum
use
design
target
nucleic
acid
photoact
chemic
alkyl
therebi
shut
function
transcriptiontransl
andor
prolifer
replic
unwant
microbi
passeng
without
necessarili
destroy
membran
cellular
therapeut
product
pathogen
virus
bacteria
fungi
protozoa
even
donor
leukocyt
function
elimin
assur
pi
nonmutagen
respect
host
crucial
method
broadli
target
nucleic
acid
integr
unless
pi
agent
harmless
human
forese
exposur
rang
relev
residu
quantiti
must
either
extract
remov
convert
harmless
byproduct
exploit
agent
avail
intrins
decay
properti
pi
process
would
appeal
could
shown
inexpens
compat
current
good
manufactur
practic
solventdeterg
inactiv
plasma
solventdeterg
inactiv
use
membranedisrupt
solvent
trinbutyl
phosphat
deterg
triton
incub
pool
plasma
thousand
donor
follow
remov
sd
oil
adsorpt
chromatographi
histor
largescal
sd
inactiv
method
unit
state
associ
increas
prothrombot
product
risk
account
undesir
incident
decreas
integr
antithrombot
plasma
protein
protein
antiplasmin
photochem
pi
plasma
andor
platelet
product
methylen
blue
mb
phenothiazin
dye
ad
individu
unit
plasma
photodynam
activ
uv
light
nm
produc
singlet
oxygen
deoxyribonucl
acid
damag
dye
intercal
free
radic
role
strand
crosslink
guanosin
oxid
indirect
depurin
like
sd
applic
mb
restrict
plasma
also
limit
pi
abil
howev
basi
limit
differ
red
blood
cell
hemolysi
occur
effect
reactiv
mb
singlet
lipid
protein
compon
membran
hand
capsid
nonenvelop
virus
membran
bacteria
protozoa
infect
leukocyt
persist
plasma
freezethaw
may
resist
perturb
mb
penetr
elimin
micropor
filter
thu
use
remov
residu
leukocyt
alongsid
dye
photoderiv
psoralen
also
photoact
planar
molecul
small
size
facilit
membran
penetr
dark
reaction
base
intercal
follow
uvadepend
light
reaction
nm
sever
minut
adduct
form
psoralen
pyrimidin
base
nucleic
acid
turn
produc
irrevers
crosslinkag
singleand
doublestrand
nucleic
acid
signific
photodegrad
prolong
h
incub
compound
absorpt
disk
affin
devic
remov
psoralen
byproduct
storag
intercept
ceru
europ
bv
leusden
netherland
amotosalen
system
test
plasma
well
platelet
remark
activ
psoralen
illustr
capac
inactiv
log
lymphocyt
disrupt
disproportion
base
pair
riboflavin
vitamin
b
like
photoact
pi
agent
bind
dna
intercal
ultraviolet
photolysi
complex
induc
guanin
oxid
singlestrand
break
format
coval
adduct
unlik
agent
toxic
concern
natur
occur
safe
compound
agent
like
previou
evalu
platelet
plasma
potenti
use
rbc
explor
success
blood
compon
would
make
uniqu
generaliz
techniqu
compar
other
pathogen
inactiv
techniqu
explor
rbc
product
pathogen
inactiv
challeng
rbc
product
hemoglobin
capabl
absorb
scatter
uv
visibl
light
red
wavelength
nm
rbc
membran
particularli
vulner
varieti
pi
techniqu
alkyl
class
deriv
quinacrin
mustard
attempt
overcom
issu
lightindepend
activ
known
frangibl
anchor
linker
effector
compound
intercal
acridin
ring
structur
link
effector
group
coval
attach
nucleic
acid
link
structur
hydrolyz
bond
capabl
releas
ring
condit
ph
chang
ie
neutral
typic
acid
storag
physiolog
level
intercept
system
one
particular
frangibl
anchor
linker
effector
helinx
ceru
corp
concord
ca
incub
rbc
hour
time
nucleic
acid
crosslink
occur
releas
degrad
product
rapidli
elimin
final
compound
remov
step
may
remain
bound
protein
within
rbc
thu
serv
immunogen
respect
acquir
preform
antibodi
unclear
signific
inactin
system
repres
anoth
pi
techniqu
use
lowmolecularweight
highli
watersolubl
cation
ethyleneimin
deriv
instantli
travers
cell
membran
damag
nucleic
acid
without
crosslink
incub
period
tail
coval
bind
neg
charg
phosphat
group
protonationactiv
aziridin
site
select
alkyl
guanosin
break
open
imidazol
ring
structur
chang
recogn
stop
signal
base
lost
strand
breakag
occur
subsequ
remov
wash
residu
mutagen
risk
antibodi
format
also
seen
although
never
appear
clinic
signific
antigen
rbc
surfac
chang
never
detect
nevertheless
clinic
trial
suspend
exponenti
model
pi
loglinear
dynam
truli
pathogen
reduct
techniqu
complet
inactiv
zero
leftov
pathogen
may
achiev
highinput
inocula
reduct
also
variabl
depend
upon
inoculum
size
speci
type
durat
pi
applic
intens
pi
ultim
restrain
potenti
collater
damag
integr
function
product
pathogen
inactiv
also
subject
error
danger
fallibl
human
process
may
lead
fail
inactiv
miss
remov
toxic
byproduct
present
john
chapman
phd
thermogenesi
corpor
rancho
cordova
ca
toxicolog
defin
studi
advers
effect
chemic
physic
biolog
agent
live
organ
ecosystem
includ
prevent
amelior
advers
event
substanc
use
inactiv
pathogen
blood
product
toxic
requir
must
select
effect
substanc
must
high
degre
lethal
wide
varieti
live
organ
might
contamin
blood
product
virus
simpl
eukaryot
parasit
time
minim
collater
injuri
normal
compon
blood
product
although
sd
treatment
disrupt
lipid
membran
option
plasma
product
viabl
approach
achiev
select
toxic
cellular
blood
product
target
nucleic
acid
sever
technolog
develop
enter
clinic
trial
mb
amotosalen
riboflavin
thionin
requir
activ
light
wherea
other
may
activ
shift
ph
eg
activ
upon
bind
neg
charg
phosphat
group
present
nucleic
acid
eg
product
demonstr
variou
degre
high
degre
select
toxic
success
inactiv
wide
varieti
transfusiontransmiss
pathogen
minim
effect
therapeut
potenc
blood
product
toxic
must
consid
includ
risk
personnel
involv
process
blood
product
risk
environ
dispos
wast
product
risk
transfus
recipi
last
risk
focu
remain
discuss
field
toxicolog
evolv
past
year
systemat
approach
character
hazard
exposur
level
doserespons
relationship
permit
meaning
risk
assess
made
modern
toxicolog
test
batteri
begin
pharmacokinet
studi
follow
assess
singledos
toxic
repeateddos
toxic
reproduct
toxic
genotox
carcinogen
detect
potenti
hazard
dosag
select
studi
rang
high
enough
induc
gener
toxic
syndrom
test
anim
weight
loss
decreas
food
consumpt
combin
result
toxic
studi
provid
comprehens
hazard
assess
compris
potenti
advers
effect
maxim
toler
dose
doserespons
relationship
toxic
effect
comprehens
risk
assess
turn
weigh
exposur
assess
involv
assumpt
regard
typic
dose
substanc
frequenc
administ
expect
durat
treatment
ideal
maximum
safe
dose
determin
anim
studi
safeti
margin
margin
account
extrapol
anim
human
physiolog
anoth
margin
account
physiolog
variat
human
anoth
margin
account
variabl
detect
toxicolog
end
point
pi
substanc
current
phase
clinic
trial
higher
toxic
studi
far
encourag
dose
threshold
acut
toxic
uvaactiv
amotosalen
exampl
mgkg
rat
mortal
mgkg
dog
central
nervou
system
effect
dose
time
higher
respect
would
deliv
typic
dose
amotosaleninactiv
blood
product
toxic
howev
safeti
margin
reproduct
toxic
determin
histolog
rather
function
assess
exampl
demonstr
threshold
mgkg
time
expect
clinic
exposur
reproduct
risk
also
found
appropri
safeti
margin
born
mind
mani
wide
use
medic
acetaminophen
safeti
margin
also
note
pi
substanc
water
solubl
rapidli
excret
therefor
trace
amount
infus
treat
blood
product
bioaccumul
pharmacokinet
character
amotosalen
publish
genotox
carcinogen
particularli
import
concern
pi
substanc
substanc
activ
target
nucleic
acid
particular
tissu
specif
carcinogen
known
caus
damag
nucleic
acid
batteri
assay
measur
chemicalinduc
dna
mutat
establish
design
genotox
assay
exampl
posit
indic
genotox
includ
induct
dna
repair
cultur
rat
hepatocyt
manifest
unschedul
dna
synthesi
induct
mutat
bacteria
ame
assay
salmonella
base
pair
substitut
frame
shift
induct
mutat
mammalian
cell
line
vitro
mous
lymphoma
assay
posit
result
assay
mean
chemic
carcinogen
increas
risk
caus
cancer
exposur
assess
particularli
import
neg
result
strong
assur
chemic
carcinogen
tradit
bioassay
rat
mice
time
consum
year
increas
interest
recent
year
assess
carcinogen
risk
directli
use
transgen
mice
heterozyg
wildtyp
gene
cancer
bioassay
mous
strain
innat
vulner
carcinogenesi
loss
tumor
suppressor
gene
rel
brief
exposur
chemic
studi
requir
tumor
format
observ
fewer
anim
need
test
cancer
model
also
advantag
provid
wholeanim
dosimetri
data
allow
research
focu
specif
molecular
event
relev
human
malign
carcinogen
pi
substanc
assess
use
mous
model
result
obtain
reassur
one
begin
assum
residu
concentr
unit
treat
rbc
patient
receiv
u
rbc
everi
week
year
would
lifetim
exposur
mgkg
studi
anim
receiv
infus
per
week
week
contrast
dose
exceed
mgkg
tumor
induct
exceed
observ
control
arm
patient
dose
would
equival
receiv
nearli
u
rbc
per
week
carcinogen
typic
human
exposur
therefor
calcul
extrapol
backward
doserespons
curv
observ
experiment
studi
unsurprisingli
degre
ad
risk
small
even
one
base
risk
assess
upper
limit
confid
interv
ci
treat
entir
us
blood
suppli
approxim
million
rbc
per
year
would
expect
result
extra
malign
everi
year
cancer
model
use
pi
compound
blood
product
treat
pi
test
pi
blood
product
import
consider
pi
substanc
particip
varieti
side
reaction
remov
blood
product
although
result
metabol
byproduct
gener
appear
less
potent
parent
compound
may
still
carri
toxic
risk
wide
safeti
margin
byproduct
imposs
confirm
tradit
vitro
genotox
studi
dose
limit
impos
volum
blood
product
model
howev
abil
expos
anim
regular
basi
period
combin
increas
suscept
mice
carcinogenesi
allow
rigor
assess
carcinogen
risk
one
experi
ml
blood
collect
weekli
basi
differ
mice
blood
volum
equival
unit
pack
rbc
treat
partial
wash
infus
seri
weekli
dose
week
mice
observ
toxic
increas
tumor
format
compar
control
anim
demonstr
rbc
product
carcinogen
similar
studi
model
report
amotosalen
inform
contrast
risk
assess
pi
substanc
ethylen
oxid
eto
steril
use
year
drug
product
medic
devic
substanc
demonstr
mutagen
carcinogen
teratogen
anim
studi
hypersensit
reaction
patient
undergo
hemodialysi
shown
strong
correl
immun
respons
eto
use
steril
dialysi
devic
nevertheless
us
fda
propos
approv
use
eto
steril
compon
cord
blood
process
system
storag
contain
long
residu
level
exceed
mg
per
devic
residu
quantiti
amotosalen
treat
platelet
contrast
wherea
residu
concentr
treat
rbc
issu
concern
eto
use
steril
dispos
process
stem
cell
review
addit
risk
describ
anoth
type
toxicolog
effect
elicit
immun
respons
pi
blood
product
occur
modif
macromolecul
cell
surfac
creat
new
antigen
neoantigen
elicit
immun
respons
result
product
antibodi
bind
blood
cell
product
caus
clear
circul
conduct
phase
trial
determin
elicit
immunolog
respons
rbc
result
technolog
put
hold
technic
issu
resolv
similar
immunolog
problem
observ
rbc
caus
delay
product
develop
effort
howev
new
trial
modifi
process
rbc
current
underway
technolog
current
toxicolog
test
strategi
work
identifi
hazard
clinic
trial
phase
drug
develop
although
pi
substanc
inde
substanc
consid
complet
nontox
avail
assay
suggest
pi
blood
product
impart
measur
toxic
signific
risk
longterm
carcinogen
patient
say
product
pose
risk
clinic
trial
rbc
treat
exampl
stop
earli
develop
posit
albeit
asymptomat
direct
antiglobulin
test
select
patient
popul
find
support
idea
current
approach
evalu
pi
technolog
preclin
studi
anim
clinic
trial
human
work
identifi
potenti
hazard
webert
et
al
whether
risk
observ
theoret
pi
blood
product
justifi
addit
benefit
safeti
provid
still
matter
discuss
howev
clear
pi
blood
product
success
complet
preclin
clinic
trial
favor
safeti
profil
compar
drug
chemic
common
use
includ
substanc
alreadi
ad
blood
product
present
christoph
prows
phd
scottish
nation
blood
transfus
servic
edinburgh
scotland
longer
clinic
experi
pi
plasma
product
rbc
platelet
part
cellular
blood
compon
pose
particular
technic
challeng
develop
pi
technolog
time
write
differ
plasma
pi
process
licens
first
involv
pool
individu
plasma
donat
treat
sd
disrupt
lipid
membran
present
envelop
pathogen
virus
second
process
requir
addit
psoralen
amotosalen
hydrochlorid
previous
known
individu
plasma
donat
subsequ
activ
uv
light
process
result
inhibit
dna
rna
replic
third
process
also
involv
addit
nucleic
acid
sensit
mb
individu
plasma
donat
subsequ
activ
visibl
light
addit
photoinactiv
process
involv
addit
riboflavin
subsequ
activ
uv
light
enter
clinic
trial
discuss
detail
much
publish
clinic
experi
pi
plasma
product
come
europ
mani
countri
regulatori
requir
either
pi
plasma
quarantin
process
collect
plasma
held
donor
retest
later
date
transfusiontransmiss
diseas
although
pi
plasma
product
previous
licens
north
america
none
current
distribut
hospit
licens
blood
collect
agenc
chemic
agent
requir
inactiv
pathogen
may
also
harm
transfus
recipi
aforement
plasma
pi
process
includ
addit
step
remov
chemic
final
product
vitro
studi
demonstr
residu
concentr
substanc
far
anim
studi
would
suggest
toxic
dose
moreov
clinic
experi
product
suggest
safe
time
write
million
unit
sd
plasma
million
unit
mbtreat
plasma
transfus
without
appar
toxic
recipi
less
clinic
experi
amotosalentr
plasma
u
infus
time
write
anoth
issu
potenti
concern
pi
technolog
creation
neoantigen
result
modif
nativ
protein
howev
although
phenomenon
observ
pi
techniqu
applic
rbc
anim
studi
human
clinic
trial
postmarket
surveil
reveal
similar
problem
avail
pi
process
appli
plasma
despit
absenc
evid
toxic
howev
sd
plasma
product
burden
addit
safeti
concern
first
relat
effect
sd
treatment
process
hemostat
equilibrium
exist
procoagul
anticoagul
protein
nativ
plasma
distribut
sd
plasma
unit
state
american
red
cross
late
follow
sever
postmarket
report
thrombosi
bleed
secondari
hyperfibrinolysi
death
particularli
patient
undergo
liver
transplant
partli
basi
report
sd
plasma
effect
withdrawn
market
unit
state
advers
event
attribut
loss
protein
antiplasmin
occur
sd
treatment
plasma
notabl
sd
plasma
product
provid
europ
made
use
somewhat
differ
process
appear
associ
advers
event
although
case
possibl
thrombot
event
patient
thrombot
thrombocytopenia
purpura
ttp
receiv
europeanmanufactur
sd
plasma
clear
whether
sd
plasma
caus
factor
perhap
importantli
studi
focus
patient
undergo
liver
transplant
ostens
higher
risk
popul
fail
document
excess
bleed
use
europeanmanufactur
sd
plasma
studi
shown
sd
plasma
product
manufactur
europ
reduc
loss
protein
antiplasmin
comparison
us
product
also
suggest
risk
usmanufactur
sd
plasma
exagger
addit
concern
sd
plasma
although
effect
known
clinic
signific
lipidenvelop
transfusiontransmit
virus
ineffect
nonlipidenvelop
virus
parvoviru
hav
pi
process
variabl
impact
pathogen
risk
transmiss
exacerb
fact
sd
plasma
batch
made
pool
individu
donat
unit
state
lot
sd
plasma
voluntarili
recal
parvoviru
contamin
although
none
case
involv
clinic
diseas
one
phase
studi
volunt
seroconvert
parvoviru
infus
sd
plasma
found
implic
lot
high
level
viremia
geql
individu
plasma
donat
sd
plasma
batch
check
parvoviru
hav
use
nat
european
union
regul
requir
lot
viremia
exceed
consider
lower
threshold
geql
discard
approxim
lot
exceed
threshold
parvoviru
note
pass
although
sd
treatment
less
effect
pi
process
bacteria
cellular
organ
pathogen
alreadi
elimin
plasma
product
via
physic
process
clear
cellular
compon
freezethaw
cycl
destroy
whatev
remain
report
bacteri
contamin
plasma
transfus
part
attribut
contamin
water
bath
use
thaw
transmiss
parvoviru
initi
donor
screen
highlight
issu
donor
pool
among
pi
plasma
product
specif
concern
sd
plasma
transfusiontransmiss
diseas
vcjd
pathogen
agent
neither
test
demonstr
elimin
avail
pi
technolog
high
number
donor
exposur
per
transfus
pool
product
especi
worri
hand
pool
also
greatli
dilut
infecti
load
present
singl
donat
possibl
level
minim
infecti
dose
particularli
pool
also
contain
neutral
antibodi
notabl
million
dose
sd
plasma
transfus
worldwid
singl
report
either
transfusiontransmiss
vcjd
transfusionrel
acut
lung
injuri
ali
trali
product
case
trali
effect
pool
demonstr
reduc
concentr
donor
antileukocyt
antibodi
thought
contribut
trali
limit
detect
pool
plasma
donor
vari
abo
group
perform
proper
proport
also
allow
product
univers
abocompat
plasma
addit
precautionari
step
avail
blood
collect
agenc
includ
import
plasma
north
america
avoid
vcjd
risk
use
plasma
male
donor
avoid
donat
higher
risk
contain
antileukocyt
antibodi
unit
kingdom
recent
adopt
import
sd
plasma
pi
plasma
product
choic
patient
ttp
despit
avers
toward
use
pool
product
unit
kingdom
due
vcjd
concern
clinic
efficaci
pi
plasma
tradit
evalu
comparison
untreat
ffp
must
acknowledg
howev
evid
base
efficaci
ffp
strong
recent
systemat
review
trial
evalu
efficaci
ffp
clinic
indic
found
adequ
support
random
control
trial
rct
ttp
standard
indic
evid
efficaci
ffp
limit
either
nonrandom
trial
massiv
transfus
dissemin
intravascular
coagul
revers
coumarin
correct
congenit
coagul
factor
defici
expert
opinion
neonat
hemorrhag
diseas
trial
identifi
either
small
inadequ
protect
bia
even
caveat
mind
evid
pi
plasma
therapeut
equival
ffp
alway
convinc
publish
clinic
studi
mb
plasma
case
report
uncontrol
observ
studi
compar
studi
mb
plasma
vs
ffp
healthi
volunt
patient
undergo
cardiopulmonari
bypass
small
insuffici
methodolog
rigor
conclud
therapeut
equival
moreov
recent
studi
compar
mb
plasma
ffp
patient
ttp
suggest
mb
plasma
may
actual
less
effect
notabl
introduct
mb
plasma
catalonia
region
spain
follow
dramat
increas
ratio
plasma
rbc
transfus
accompani
grow
demand
fibrinogen
form
cryoprecipit
implic
observ
mb
plasma
reduc
hemostat
qualiti
perhap
due
loss
fibrinogen
observ
mb
treatment
nativ
plasma
experi
elsewher
show
littl
differ
use
ffp
mb
plasma
extens
experi
mb
plasma
europ
would
tend
support
observ
although
licens
pi
plasma
product
approxim
less
coagul
factor
viii
nativ
plasma
unlik
clinic
signific
except
patient
congenit
factor
viii
defici
evid
suggest
clinic
efficaci
sd
plasma
also
rel
weak
although
sever
publish
rct
control
observ
studi
suggest
equival
ffp
studi
underpow
postmarket
surveil
republ
ireland
sd
plasma
introduc
rais
concern
regard
inadequ
hemostasi
sever
highrisk
popul
women
obstetr
gynecolog
emerg
critic
ill
neonat
patient
liver
diseas
although
less
clinic
experi
amotosalen
plasma
licens
pathogeninactiv
plasma
product
trial
evalu
clinic
efficaci
rigor
design
one
observ
studi
transfus
amotosalen
plasma
achiev
increment
coagul
factor
recoveri
compar
ffp
except
fibrinogen
prothrombin
factor
xiii
provid
clinic
effect
hemostasi
subsequ
rct
amotosalen
plasma
vs
ffp
patient
acquir
coagulopathi
predominantli
patient
liver
diseas
show
noninferior
correct
prothrombin
time
although
statist
noninferior
demonstr
correct
activ
partial
thromboplastin
time
fact
trend
toward
greater
efficaci
amotosalen
plasma
differ
clinic
outcom
observ
separ
rct
compar
amotosalen
plasma
ffp
treatment
ttp
differ
clinic
outcom
observ
although
studi
underpow
prove
noninferior
cost
one
take
account
virus
screen
transfus
servic
margin
cost
effect
sd
plasma
probabl
pi
plasma
product
gener
astronom
nu
per
qualityadjust
lifeyear
qali
sd
plasma
avoid
trali
may
reduc
accept
level
approxim
us
per
qali
untest
emerg
pathogen
theoret
benefit
pi
plasma
use
test
avoid
difficult
quantifi
licens
pi
plasma
product
effect
reduc
pathogen
load
clinic
insignific
level
clinic
signific
lipidenvelop
virus
residu
risk
hav
parvoviru
sd
plasma
address
enhanc
donor
screen
solventdeterg
plasma
requir
pool
individu
donor
may
increas
risk
untest
noninactiv
pathogen
vcjd
may
decreas
risk
trali
toxic
neoantigen
induct
concern
date
despit
extens
clinic
experi
sd
plasma
mb
plasma
preliminari
experi
amotosalen
plasma
pathogen
inactiv
plasma
induc
loss
potenc
exampl
factor
viii
one
sd
plasma
product
longer
market
loss
protein
antiplasmin
associ
advers
clinic
event
qualiti
trial
evalu
efficaci
pi
plasma
vs
ffp
histor
poor
improv
recent
year
present
sherril
slichter
md
puget
sound
blood
centr
seattl
wa
efficaci
pi
platelet
evalu
vitro
vivo
studi
vitro
studi
rare
reflect
happen
vivo
vivo
studi
discuss
vivo
studi
use
assess
platelet
viabil
function
platelet
viabil
usual
evalu
first
perform
autolog
radiolabel
platelet
recoveri
surviv
measur
healthi
volunt
studi
complet
platelet
transfus
studi
thrombocytopen
patient
conduct
determin
platelet
viabil
assess
posttransfus
platelet
increment
correct
count
increment
day
next
transfus
vivo
hemostat
function
transfus
platelet
given
thrombocytopen
patient
evalu
bleed
time
measur
correl
preand
posttransfus
platelet
count
direct
visual
andor
diagnost
assess
bleed
within
multipl
organ
system
red
cell
transfus
requir
studi
shown
pi
platelet
inferior
platelet
recoveri
surviv
compar
convent
platelet
studi
goodrich
et
al
autolog
platelet
collect
healthi
volunt
apheresi
platelet
prepar
n
without
n
prestorag
pi
procedur
store
day
pi
procedur
use
dose
riboflavin
vari
dose
uva
exposur
jml
healthi
volunt
jml
healthi
volunt
end
storag
platelet
label
indium
reinfus
pathogen
inactiv
platelet
significantli
lower
percentag
recoveri
shorter
surviv
similarli
store
convent
platelet
uva
dose
p
b
measur
moreov
increas
uva
dose
produc
logarithm
decreas
posttransfus
platelet
recoveri
surviv
result
keep
singleblind
crossov
platelet
storag
studi
aubuchon
et
al
indiumradiolabel
autolog
platelet
recoveri
surviv
statist
significantli
lower
measur
p
volunt
receiv
platelet
treat
riboflavin
jml
uva
vs
convent
platelet
platelet
recoveri
vs
surviv
vs
day
respect
snyder
observ
similar
outcom
platelet
treat
amotosalen
jml
uva
indiumradiolabel
autolog
store
platelet
recoveri
surviv
statist
significantli
lower
p
b
treat
vs
convent
platelet
platelet
recoveri
vs
surviv
vs
day
respect
hand
neither
use
compound
absorpt
devic
remov
residu
amotosalen
degrad
product
neg
impact
viabil
pathogentr
platelet
headtohead
comparison
riboflavinuvav
amotosalenuvatr
platelet
howev
compar
data
studi
aubuchon
et
al
snyder
et
al
platelet
recoveri
somewhat
better
riboflavinuvatr
platelet
wherea
platelet
surviv
slightli
better
amotosalenuvatr
platelet
riboflavinuvatr
platelet
platelet
recoveri
surviv
reduc
respect
compar
correspond
convent
autolog
radiolabel
platelet
transfus
studi
similar
data
amotosalenuvatr
platelet
demonstr
reduct
platelet
recoveri
surviv
respect
assumpt
transfus
platelet
abl
maintain
hemostasi
correl
platelet
count
bleed
time
demonstr
previous
examin
vivo
platelet
function
amotosalenuvatr
platelet
bleed
time
compar
thrombocytopen
patient
transfus
random
order
amotosalenuvatr
platelet
convent
platelet
pretransfus
bleed
time
platelet
count
similar
group
statist
signific
differ
bleed
time
hour
posttransfus
treat
vs
convent
platelet
moreov
studi
demonstr
robust
direct
relationship
posttransfus
platelet
count
bleed
time
treat
convent
platelet
final
pi
platelet
shown
noninferior
convent
platelet
reduc
bleed
thrombocytopen
patient
sprint
trial
larg
multicent
rct
chronic
thrombocytopen
patient
assign
receiv
either
pathogentr
apheresi
platelet
amotosalenuva
n
convent
apheresi
platelet
n
day
primari
outcom
measur
incid
world
health
organ
grade
bleed
statist
signific
differ
patient
treat
arm
vs
patient
convent
arm
incid
world
health
organ
grade
bleed
differ
observ
studi
arm
patient
treat
arm
vs
patient
convent
arm
number
red
cell
transfus
given
arm
vs
respect
hand
posttransfus
platelet
count
vs
platelet
increment
vs
correct
count
increment
vs
hour
posttransfus
significantli
lower
treat
vs
convent
arm
data
provid
p
b
valu
hour
posttransfus
differ
posttransfus
platelet
respons
part
could
explain
fact
patient
treat
arm
receiv
slightli
lower
mean
platelet
mean
dose
vs
platelet
per
transfus
p
b
patient
treat
arm
also
shorter
mean
interv
transfus
vs
day
respect
p
b
thu
receiv
platelet
transfus
per
patient
vs
respect
p
b
conclus
pi
use
uva
exposur
either
amotosalen
riboflavin
result
statist
signific
decreas
autolog
platelet
recoveri
respect
surviv
respect
loss
platelet
viabil
pi
use
amotosalenuva
confirm
larg
transfus
trial
thrombocytopen
patient
patient
receiv
treat
platelet
compar
patient
receiv
convent
platelet
statist
signific
decreas
posttransfus
platelet
count
interv
transfus
result
need
platelet
transfus
could
partial
account
lower
mean
platelet
dosetransfus
patient
receiv
treat
platelet
howev
spite
poorer
platelet
respons
amotosalenuvatr
platelet
compar
convent
platelet
abil
maintain
hemostasi
evidenc
assess
bleed
time
measur
clinic
evid
bleed
rbc
transfus
requir
thrombocytopen
patient
present
jeanpierr
cazenav
md
du
sangalsac
strasbourg
franc
intercept
blood
system
platelet
use
amotosalen
uva
pathogeninactiv
either
leukoreduc
apheresi
platelet
compon
apclr
plasma
intersol
ceru
corp
leukoreduc
buffi
coat
platelet
compon
bcpclr
plasma
intersol
accord
intern
confer
harmonis
pharmaceut
standard
number
clinic
trial
intercept
platelet
complet
healthi
subject
thrombocytopen
patient
europ
unit
state
largest
number
evalu
transfus
pool
buffi
coat
platelet
compon
prepar
photochem
pathogen
inactiv
studi
eurosprit
phase
rct
n
center
therapeut
efficaci
safeti
platelet
treat
photochem
process
pathogen
inactiv
studi
sprint
phase
rct
n
respect
primari
end
point
count
increment
compar
equival
dose
intercept
convent
buffi
coat
platelet
p
secondari
end
point
similarli
compar
platelet
transfus
refractori
acut
transfus
reaction
intertransfus
interv
rbc
transfus
requir
hemorrhag
analog
phase
evalu
apheresi
platelet
without
pi
reveal
similar
primari
secondari
end
point
platelet
concentr
obtain
intercept
blood
system
either
apheresi
platelet
collect
whole
bloodderiv
buffi
coat
platelet
pool
demand
less
minut
handson
time
permit
sameday
overnight
nextday
process
intersol
platelet
addit
solut
maxim
divert
plasma
yield
donor
hope
reduc
plasma
content
platelet
may
reduc
transfus
reaction
platelet
content
unit
volum
ml
less
residu
amotosalen
final
product
regulatori
statu
product
includ
mark
registr
agenc
de
sanitair
de
produit
de
approv
paulehrlichinstitut
pei
market
author
germani
du
sang
ef
french
nation
transfus
servic
consist
region
blood
center
franc
oversea
center
ile
de
la
martiniqu
guadeloup
french
guyana
transfus
platelet
dose
rapid
introduct
week
may
intercept
pi
platelet
efsil
de
la
ration
emerg
chikungunya
viru
specif
test
avail
although
efsnord
de
franc
abl
export
plasma
rbc
rapid
transport
platelet
use
averag
platelet
concentr
per
month
feasibl
implement
train
personnel
requir
addit
staff
impact
platelet
use
although
reduc
rate
acut
transfus
reaction
product
observ
efsalsac
larg
blood
center
transfus
u
platelet
annual
buffycoattoapheresi
ratio
also
adopt
intercept
blood
system
platelet
without
complic
juli
date
intercept
platelet
concentr
transfus
patient
process
loss
ml
platelet
impact
platelet
use
requir
cytomegaloviru
cmv
serolog
unnecessari
sixunit
pool
bcpclr
distribut
median
day
day
product
releas
apclr
day
clinician
respons
posit
acut
reaction
reduc
vs
untreat
platelet
concentr
tsol
baxter
healthcar
corp
lessin
belgium
untreat
platelet
concentr
origin
plasma
report
episod
trali
bacteri
sepsi
death
ef
nation
strategi
train
center
excel
adopt
technolog
transit
addit
solut
increas
plasma
fraction
reduc
transfus
reaction
dose
intercept
platelet
transfus
center
across
countri
intercept
plasma
undergo
valid
studi
european
blood
center
net
cost
may
balanc
shift
apclr
bcpclr
lack
requir
bacteri
detect
measur
cmv
serolog
test
new
test
hbv
nat
protozo
test
chaga
malaria
leishmania
need
adopt
donor
deferr
criteria
may
becom
less
stringent
inclus
without
sacrif
confid
protect
reemergingemerg
infect
avian
influenza
sever
acut
respiratori
syndrom
chikungunya
viru
summari
intercept
system
adopt
rapidli
success
small
larg
region
blood
center
reassur
qualiti
control
process
accept
net
cost
gain
intend
benefit
pi
noninferior
superior
observ
acut
transfus
reaction
rate
present
jame
p
aubuchon
md
dartmouthhitchcock
medic
center
lebanon
nh
new
rbc
collect
prepar
storag
system
usual
subject
vitro
vivo
analys
determin
suitabl
clinic
applic
regulatori
agenc
attempt
document
safeti
efficaci
system
part
assess
author
clinic
use
jurisdict
focu
present
approach
use
fda
unit
state
fda
use
situationspecif
approv
criteria
requir
progress
extens
test
substanti
chang
establish
approach
propos
gener
speak
increas
risk
patient
impact
complex
test
requir
new
technolog
exampl
minor
chang
exist
technolog
may
requir
vitro
test
wherea
major
chang
introduct
pi
technolog
requir
vivo
experi
eg
radiolabel
autolog
recoveri
surviv
well
patient
clinic
trial
establish
safeti
efficaci
success
junctur
may
lead
licensur
howev
fda
may
addit
requir
implement
postmarket
surveil
program
detect
rare
event
situat
approach
assur
agenc
manufactur
system
perform
expect
proceed
new
level
test
maxim
likelihood
success
minim
risk
subjectspati
next
test
level
fda
current
use
absolut
rel
criteria
assess
outcom
requir
test
absolut
criteria
specifi
hemolysi
must
less
end
storag
residu
leukocyt
content
less
u
leukoreduc
unit
postfiltr
rbc
recoveri
origin
rbc
mass
confid
least
popul
unit
meet
requir
criteria
assess
rel
basi
judg
control
popul
unit
previous
licens
system
trial
power
detect
differ
analys
includ
standard
hematolog
paramet
concentr
rbc
wbc
platelet
concentr
adenosin
triphosph
atp
glucos
lactat
well
determin
ph
morpholog
score
absolut
criteria
arbitrari
adequ
appropri
rel
criteria
provid
interest
inform
limit
util
exampl
atp
concentr
shown
predict
rbc
recoveri
dichotom
function
day
level
necessari
viabil
vivo
recoveri
long
regard
gold
standard
viabil
proport
chromium
rbc
remain
circul
hour
autolog
reinfus
determin
estim
total
rbc
mass
dilutionback
extrapol
singlelabel
recoveri
slr
actual
determin
simultan
infus
technetiumlabel
freshli
collect
rbc
doublelabel
techniqu
dlr
doublelabel
techniqu
provid
improv
accuraci
particularli
lower
recoveri
wherea
slr
simpler
quicker
subject
research
associ
less
radiat
exposur
less
expens
analysi
pair
comparison
slr
dlr
recoveri
reveal
result
obtain
method
statist
significantli
differ
howev
differ
small
slr
produc
recoveri
percentag
point
higher
dlr
issu
explor
futur
studi
biomed
excel
safer
transfus
best
collabor
determin
longterm
surviv
rbc
usual
requir
biochem
integr
rbc
may
affect
pi
requir
rbc
vivo
recoveri
evolv
year
mean
recoveri
hour
reinfus
radiolabel
rbc
establish
standard
without
much
support
scientif
evid
year
mean
increas
recoveri
recoveri
lower
bound
ci
current
criteria
call
mean
recoveri
sd
less
ci
lower
confid
limit
popul
proport
success
case
n
least
site
new
requir
appear
pose
signific
hurdl
mani
current
use
system
could
meet
best
collabor
current
collect
data
rbc
recoveri
blood
system
current
use
unit
state
propos
requir
variat
examin
determin
aspect
tripartit
concept
present
greatest
challeng
rbc
surviv
assumpt
rbc
circul
surviv
normal
surviv
studi
present
number
challeng
requir
prolong
week
dedic
subject
one
well
radioact
decay
label
elut
may
need
taken
account
current
fda
requir
rbc
surviv
studi
major
alter
blood
system
pi
technolog
repres
major
alter
rbc
surviv
studi
may
necessari
pathogen
inactiv
agent
abl
affect
biolog
system
surpris
rbc
pi
system
appear
reduc
viabil
exampl
inactin
result
rbc
recoveri
differ
control
acceler
clearanc
circul
beyond
hour
approxim
one
third
origin
treatment
process
result
slight
decreas
recoveri
vs
control
unchang
surviv
howev
process
result
gener
antibodi
direct
moieti
deposit
rbc
membran
chemic
interact
led
abandon
inactin
revis
process
yield
rbc
nonreact
antiacridin
antibodi
revis
techniqu
current
undergo
trial
get
someth
noth
appropri
trade
pi
reduc
efficaci
rbc
circul
balanc
benefit
reduc
infecti
risk
question
panel
deliber
fda
signal
reduc
efficaci
could
toler
detail
commit
polici
yet
known
nevertheless
current
system
use
evalu
rbc
system
provid
use
predict
cellular
viabil
one
process
leukoreduct
achiev
process
describ
lublin
shown
great
promis
laboratori
limit
clinic
trial
anim
human
pathogen
inactiv
procedur
particular
led
vitro
serolog
problem
treat
rbc
crossmatch
use
human
sera
unexpect
given
human
sera
contain
amaz
varieti
antibodi
chemic
presenc
probabl
due
environment
exposur
chemic
eg
polyethylen
glycol
present
wide
varieti
food
cosmet
thu
antibodi
found
healthi
donor
patient
antibodi
present
inadvert
immun
chemic
use
pi
process
would
involv
mechan
occur
druginduc
immun
reaction
antibodi
could
direct
chemicaldrug
eg
penicillininduc
serolog
combin
chemic
rbc
membran
two
possibl
chemicaldrug
may
chang
rbc
membran
creat
new
antigen
neoantigen
chang
rbc
membran
may
adsorb
protein
nonimmunolog
lead
posit
antiglobulin
test
vitro
possibl
vivo
mechan
observ
pi
process
although
evid
antibodi
neoantigen
slim
find
antibodi
due
phenomena
eg
natur
occur
antibodi
chemic
druginduc
antibodi
immun
respons
chemic
use
pi
necessarili
mean
decreas
rbc
surviv
occur
exampl
clinic
signific
insignific
antibodi
categori
describ
avail
pi
procedur
best
document
exampl
immunogen
rbc
problem
encount
clinic
trial
intercept
system
incompat
crossmatch
found
due
antibodi
chemic
remain
rbc
surfac
process
close
relat
acriflavin
dye
ad
antib
blood
type
reagent
year
ago
caus
serolog
anomali
antibodi
acriflavin
antibodi
found
patient
like
clinic
signific
patient
asymptomat
monocyt
monolay
rbc
phagocyt
assay
neg
serolog
issu
clinic
trial
place
stop
result
modifi
process
reduc
bind
rbc
surfac
develop
compani
sera
patient
reactiv
react
modifiedprocess
rbc
hyperimmun
rabbit
model
rbc
surviv
normal
clinic
trial
modifiedprocess
rbc
current
progress
serolog
problem
pi
similar
problem
encount
immunohematolog
year
subject
rbc
vitro
process
lead
antigenantibodi
reaction
provid
antigen
form
rbcbound
chemic
neoantigen
nonimmunolog
bind
protein
difficult
imposs
predict
serolog
problem
use
anim
model
addit
immun
respons
chemic
may
occur
patient
even
compani
fulfil
fda
requir
crossmatch
problem
may
still
occur
futur
incid
may
higher
incid
alloantibodi
rbc
antigen
decisionmak
approach
use
sort
issu
rbc
blood
group
antibodi
import
data
evalu
rbc
surviv
transfus
rbc
determin
immun
rbc
destruct
webert
et
al
recoveri
suffic
rbc
surviv
studi
also
necessari
present
walter
h
sunni
dzik
md
massachussett
gener
hospit
boston
impact
import
urgenc
pathogen
reduct
method
improv
overal
safeti
transfus
best
assess
context
infecti
noninfecti
hazard
data
present
frequenc
noninfecti
risk
transfus
cost
technolog
avail
reduc
risk
data
use
establish
prioriti
pathogen
reduct
technolog
amid
measur
design
improv
transfus
safeti
hemovigil
program
provid
us
best
estim
transfus
risk
one
system
seriou
hazard
transfus
shot
unit
kingdom
central
gather
classifi
voluntari
report
advers
transfus
event
hospit
sinc
anoth
hemovigil
program
direct
institut
nation
de
publiqu
quebec
canada
sinc
program
review
everi
inhospit
advers
transfus
event
report
local
transfus
safeti
offic
use
inform
technolog
system
share
region
hospit
provinc
quebec
program
invari
found
continu
threat
transfus
safeti
noninfecti
fig
incorrect
blood
compon
transfus
ibct
account
largest
proport
seriou
transfus
hazard
implic
human
error
underscor
higher
incid
error
pretransfus
test
blood
administr
outsid
core
hour
major
morbid
death
due
transfus
error
often
due
ibct
hemolyt
complic
trali
transfusiontransmit
infect
contrast
compris
seriou
hazard
report
shot
seriou
hazard
transfus
found
ibct
event
abo
mistransfus
quebec
hemovigil
report
nearli
abo
mistransfus
due
failur
proper
identif
transfus
patient
remain
minor
divid
laboratori
cleric
technic
event
error
patient
identif
occur
specimen
collect
error
well
time
blood
administr
error
address
sampl
miscollect
error
occur
everi
specimen
submit
blood
bank
institut
adopt
polici
transfus
group
blood
least
ident
abo
type
obtain
patient
address
substanti
problem
patient
misidentif
time
transfus
like
requir
use
machineread
technolog
although
technolog
commonplac
throughout
commerci
secur
enterpris
unfortun
unusu
bedsid
patient
care
cost
implement
hospitalwid
pretransfus
bedsid
posit
patient
identif
use
barcod
technolog
may
extrapol
experi
john
radcliff
hospit
unit
kingdom
equip
train
mainten
servic
life
technolog
approxim
per
transfus
unit
blood
acut
delay
hemolyt
transfus
reaction
commonli
report
hemovigil
program
quebec
experi
hemolyt
reaction
due
abo
incompat
balanc
due
alloimmun
autoimmun
hemolysi
delay
hemolyt
transfus
reaction
commonli
result
antibodi
previous
identifi
longer
reactiv
pretransfus
specimen
prevent
reaction
depend
upon
retriev
data
patient
blood
bank
record
patient
receiv
health
care
multipl
hospit
share
data
regard
prior
sensit
blood
group
hospit
would
expect
reduc
rate
hemolyt
reaction
strategi
put
test
quebec
hospit
blood
bank
given
access
common
databas
patient
record
period
importantli
incid
acut
delay
hemolyt
transfus
reaction
significantli
decreas
implement
onlin
interhospit
databas
reaction
cut
cost
approxim
per
rbc
per
compon
transfus
p
robillard
person
commun
central
data
registri
could
also
store
data
obtain
highthroughput
gene
chip
technolog
appli
donor
recipi
antigen
type
prospect
match
may
decreas
hemolyt
event
reduc
rate
alloimmun
rbc
antigen
transfusionrel
ali
wide
recogn
seriou
noninfecti
hazard
lead
caus
transfusionrel
mortal
strongli
associ
passiv
transfer
donor
human
leukocyt
antigen
hla
alloantibodi
option
prevent
includ
screen
question
donor
questionnair
risk
factor
hla
sensit
multipar
laboratori
screen
hla
antibodi
among
atrisk
donor
rhode
island
blood
center
provid
previous
pregnant
donor
test
hla
antibodi
donat
test
posit
transfus
program
remark
inexpens
program
cost
estim
per
donor
correspond
increment
cost
per
compon
transfus
expect
result
inventori
lowrisk
compon
prepar
among
donor
compar
pi
impos
addit
per
unit
cost
technolog
design
reduc
risk
misidentif
error
hemolyt
transfus
reaction
trali
expens
tabl
increment
cost
per
unit
appear
least
higher
pi
compar
technolog
noninfecti
hazard
combin
one
consid
seriou
infecti
hazard
least
less
common
seriou
noninfecti
hazard
increment
cost
prevent
seriou
advers
transfus
event
may
time
higher
pi
technolog
compar
technolog
combin
health
care
fund
finit
strategi
priorit
avail
transfus
safeti
technolog
import
appropri
decis
regard
pi
technolog
need
made
context
overal
transfus
safeti
blood
recipi
fda
encourag
pathogen
reduct
transfus
product
current
approv
method
develop
novel
technolog
current
approv
method
includ
donor
screen
risk
infecti
diseas
skin
disinfect
asept
collect
use
divers
pouch
close
system
detect
use
donor
test
marker
infecti
diseas
antibodi
antigen
andor
nucleic
acid
hcv
hbv
human
tcell
leukotroph
viru
iii
cmv
wnv
cruzi
syphili
bacteri
detect
novel
technolog
yet
approv
includ
altern
store
condit
coldstor
platelet
rapid
bacteri
detect
point
releas
pi
chemic
addit
concern
novel
pi
method
process
creat
novel
mixtur
chemic
biolog
product
could
infus
intraven
wide
rang
patient
abbrevi
ibct
incorrect
blood
compon
transfus
ppi
posit
patient
identif
rfid
radiofrequ
identif
trali
transfusionrel
acut
lung
injuri
hla
human
leukocyt
antigen
webert
et
al
differ
age
differ
state
health
import
consider
implement
process
includ
efficaci
pi
process
pathogen
efficaci
treat
product
safeti
handler
pi
chemic
environ
recipi
treat
product
result
potenti
decreas
product
efficaci
impact
blood
suppli
increas
patient
exposur
blood
product
fda
perspect
aim
pi
valid
provid
direct
evid
pi
process
effect
inactiv
reduc
pathogen
could
transmit
transfus
product
indirect
evid
pathogen
reduct
process
capac
inactiv
reduc
novel
yetunidentifi
agent
vitro
studi
efficaci
demonstr
log
kill
pathogen
transfus
product
rang
log
includ
evalu
viral
bacteri
protozo
pathogen
demonstr
final
market
devic
acknowledg
conduct
clinic
studi
determin
infect
rate
patient
popul
would
requir
extrem
larg
number
current
low
rate
infect
set
nat
would
requir
approv
evalu
transfus
product
efficaci
pi
treatment
must
perform
clinic
trial
pi
chemic
may
mani
site
interact
transfus
product
full
extent
damag
product
may
evid
individu
vitro
test
initi
studi
address
product
efficaci
postpi
treatment
radiolabel
studi
exampl
fda
introduc
new
standard
evalu
new
platelet
product
use
radiolabel
platelet
studi
recoveri
hour
healthi
volunt
least
surviv
least
fresh
platelet
certain
case
novel
platelet
product
meet
radiolabel
accept
criteria
limit
clinic
applic
may
still
approv
product
clear
benefit
would
offset
loss
efficaci
phase
clinic
trial
conduct
demonstr
clinic
efficaci
pitreat
product
patient
popul
requir
repeat
transfus
product
function
end
point
ie
control
hemostasi
trial
assess
platelet
product
oxygen
deliveri
trial
assess
rbc
well
transfus
end
point
ie
frequenc
transfus
transfus
increment
toxic
recipi
pitreat
product
may
occur
parent
compound
metabolit
andor
treat
transfus
product
mixtur
gener
toxic
potenti
mutagen
carcinogen
teratogen
effect
requir
evalu
guidanc
document
design
interpret
studi
found
fda
center
drug
evalu
research
web
site
caveat
test
model
toxic
healthi
organ
may
predict
toxic
stress
diseas
organ
transfus
product
infus
patient
signific
underli
diseas
potenti
differ
toxic
profil
addit
mention
toxic
studi
pr
process
also
evalu
model
mimic
physiolog
stress
induc
variou
clinic
situat
one
exampl
would
anim
model
plateletmedi
organ
toxic
ali
murin
model
model
platelet
mediat
pathophysiolog
acidor
septicemiainduc
ali
anchor
neutrophil
lung
endotheli
cell
platelet
pselectin
mediat
neutrophil
accumul
lung
hypothesi
platelet
express
pselectin
could
support
neutrophil
accumul
lung
exacerb
ali
symptom
hypothet
clinic
scenario
reflect
mechan
could
appli
immunosuppress
thrombocytopen
patient
develop
sepsi
mild
ali
pitreat
platelet
higher
pselectin
express
control
platelet
set
infus
pitreat
platelet
could
exacerb
ali
symptom
exampl
model
implic
platelet
pathophysiolog
diseas
includ
mous
model
allerg
pneumon
ischemiareperfus
model
preclin
trial
clinic
trial
monitor
advers
event
identifi
unexpect
toxic
evalu
immun
respons
antibodi
develop
acknowledg
lowfrequ
event
may
detect
preclin
clinic
studi
requir
postmarket
surveil
studi
analysi
risk
vs
benefit
use
pi
transfus
product
also
requir
current
benefit
pi
would
includ
reduct
transfusiontransmit
diseas
bacteria
repres
highest
current
risk
septic
reaction
per
product
benefit
would
need
weigh
accept
risk
advers
event
would
anticip
much
smaller
studi
detect
advers
event
frequenc
would
unlik
would
requir
particip
nevertheless
justif
request
indepth
safeti
evalu
pi
product
clinic
studi
revolv
around
follow
argument
benefit
deriv
pi
process
rel
small
safe
blood
suppli
advers
event
associ
treat
transfus
product
would
need
low
frequenc
accept
avail
data
indic
pi
platelet
activ
increas
pselectin
express
damag
decreas
recoveri
surviv
current
avail
anim
model
present
plausibl
mechan
involv
activ
platelet
mediat
respiratori
advers
event
similar
seen
larg
clinic
trial
pitreat
platelet
elucid
current
safeti
profil
pitreat
rbc
platelet
product
argu
justifi
agener
clinic
use
oftheproduct
time
howev
may
specif
clinic
indic
benefit
pi
product
would
outweigh
potenti
high
advers
event
rate
exampl
emerg
transfusiontransmit
pathogen
epidem
high
mortal
rate
specif
patient
popul
may
suscept
transfusiontransmit
infect
summari
fda
current
perspect
regul
pi
process
requir
defin
pathogen
reduct
capac
loss
transfus
product
efficaci
postpi
treatment
toxic
advers
event
rate
preclin
clinic
trial
current
risk
transfus
transmit
diseas
riskbenefit
balanc
pi
process
determin
riskbenefit
balanc
favor
pi
process
would
approv
provis
limit
use
base
transfus
product
efficaci
request
phase
postmarket
studi
advers
event
monitor
riskbenefit
deem
unfavor
approv
could
consid
situat
transfusiontransmit
diseas
risk
would
increas
case
emerg
pathogen
epidem
present
margareth
heiden
md
paulerlichinstitut
langen
germani
blood
establish
europ
must
abid
minim
requir
set
direct
european
parliament
council
key
legisl
document
respect
blood
blood
compon
amend
technic
direct
set
standard
blood
collect
test
process
storag
distribut
blood
compon
addit
legal
bind
direct
defin
standard
medic
devic
blood
collect
bag
vitro
diagnost
screen
test
moreov
nation
may
sometim
stringent
regul
transfus
system
exampl
germani
collect
test
use
blood
compon
govern
german
transfus
act
product
distribut
blood
compon
hand
regul
german
drug
law
blood
bank
requir
appli
region
author
manufactur
licens
blood
compon
view
proprietari
medicin
product
requir
market
author
pei
german
feder
agenc
obtain
market
author
germani
new
technolog
pertain
blood
compon
prepar
must
assess
approv
pei
case
pi
technolog
pei
requir
preclin
pharmacolog
toxicolog
studi
well
clinic
studi
conduct
applic
approv
pathogeninactiv
compon
exhibit
stateoftheart
qualiti
confirm
experiment
data
safeti
base
experiment
preclin
data
experiment
data
valid
viru
reduct
clinic
data
efficaci
base
clinic
data
show
noninferior
prespecifi
clinic
outcom
gener
depend
result
assess
market
author
could
grant
follow
condit
introduct
addit
inprocess
control
inclus
specif
safeti
inform
packag
leaflet
requir
postmarket
surveil
condit
approv
review
year
point
full
approv
may
grant
januari
mbuv
lighttreat
ffp
amotosalenuv
lighttreat
platelet
condit
approv
pei
product
requir
postmarket
surveil
advers
event
addit
safeti
inform
indic
packag
insert
exampl
packag
insert
mbuv
lighttreat
ffp
state
treat
ffp
may
less
effect
untreat
ffp
especi
use
massiv
transfus
plasma
exchang
packag
insert
amotosalenuv
lighttreat
platelet
caution
use
newborn
hyperbilirubinemia
also
remind
user
risk
transmiss
nonenvelop
virus
certain
bacteri
speci
bacteri
spore
elimin
pi
product
user
remind
pi
obviat
test
hcv
hbv
syphili
care
consider
pei
recommend
univers
implement
pi
blood
compon
agenc
felt
blood
suppli
germani
alreadi
safe
introduct
minipool
nat
residu
risk
hcv
million
million
respect
moreov
report
transfusiontransmit
hivor
hcv
past
year
contrast
bacteri
contamin
continu
account
signific
portion
sever
transfus
reaction
case
includ
death
report
unfortun
screen
bacteri
contamin
elimin
problem
pathogen
inactiv
also
would
abl
prevent
case
bacteria
applic
data
bacteri
spore
appear
resist
amotosalenuv
treatment
institut
felt
introduct
current
pi
technolog
elimin
need
bacteri
detect
test
transfusiontransmit
virus
despit
extrem
low
risk
transfusiontransmit
infecti
diseas
pei
felt
import
review
give
condit
approv
pi
technolog
technolog
expect
enhanc
safeti
blood
suppli
case
error
test
failur
moreov
could
potenti
protect
blood
suppli
emerg
pathogen
test
yet
exist
final
felt
pi
technolog
could
becom
paramount
test
transmiss
diseas
interrupt
pandem
anoth
public
health
emerg
present
peter
ganz
phd
director
centr
biolog
evalu
health
canada
ottawa
ontario
canada
given
blood
system
histori
blood
safeti
consid
paramount
import
health
canadian
health
canada
ottawa
ontario
canada
regul
canadian
blood
suppli
system
provid
regulatori
oversight
appropri
scienc
base
proactiv
risk
base
flexibl
consult
interest
affect
stakehold
essenti
health
canada
regulatori
process
pathogen
inactiv
technolog
technolog
aim
inactiv
known
andor
unknown
bloodborn
pathogen
blood
product
whole
blood
blood
compon
plasma
improv
safeti
product
technolog
develop
reduc
risk
transmiss
infecti
agent
detect
current
screen
test
technolog
design
take
advantag
fact
labil
compon
blood
contain
dna
rna
therefor
treatment
target
dna
andor
rna
pathogen
neg
impact
function
rbc
platelet
plasma
variou
pi
technolog
avail
discuss
elsewher
gener
process
involv
addit
chemic
compound
transfus
product
compound
interact
nucleic
acid
pathogen
inactiv
spontan
exposur
light
energi
usual
also
nucleic
acid
crosslink
event
prevent
transcript
replic
rna
andor
dna
exist
technolog
includ
chemic
nucleic
acid
inactiv
psoralen
riboflavin
binari
ethyleneimin
alkal
agent
sd
treatment
pasteur
ozon
radiat
regulatori
review
process
pi
technolog
canada
follow
requir
defin
canadian
regul
exampl
technolog
function
devic
compon
process
defin
medic
devic
regul
devic
intend
pi
blood
classifi
class
iv
medic
devic
accord
rule
schedul
part
medic
devic
regul
technolog
function
drug
compon
regulatori
review
process
defin
food
drug
act
regul
gener
issu
import
consid
review
new
pi
technolog
safeti
qualiti
efficaci
safeti
qualiti
refer
absenc
toxic
recipi
well
absenc
toxic
compon
efficaci
refer
efficaci
compon
well
efficaci
pi
process
assess
safeti
qualiti
kind
data
requir
support
lack
toxic
recipi
fall
major
categori
gener
toxic
residu
inactiv
substanc
anim
studi
genotox
vitro
vivo
carcinogen
long
term
anim
reproduct
toxic
effect
fetu
immun
toxic
alkyl
protein
bind
lipid
rais
antibodi
neoantigen
even
extens
preclin
clinic
work
postmarket
studi
like
need
evalu
longterm
safeti
assess
potenti
toxic
treat
compon
includ
evalu
potenti
toxic
due
cell
remnant
result
damag
due
process
direct
effect
inactiv
substanc
potenti
effect
treat
cellular
compon
function
condit
treat
compon
potenti
effect
blood
plasma
protein
eg
decreas
level
protein
c
protein
due
sd
treatment
techniquesubst
characterist
analys
risk
benefit
must
undertaken
consider
evalu
includ
componentspecif
benefit
risk
vs
benefit
vulner
patient
neonat
prematur
infant
pregnant
patient
geograph
consider
eg
malaria
chaga
diseas
expect
patient
surviv
assess
effect
efficaci
inactiv
process
must
evalu
determin
effect
differ
pathogen
appropri
repres
pathogen
bloodborn
envelop
nonenvelop
virus
bacteria
parasit
must
chosen
use
demonstr
effect
qualit
quantit
log
reduct
expect
log
reduct
addit
evalu
loss
cellular
compon
process
potenti
effect
treat
compon
well
function
condit
treat
compon
must
perform
evalu
toxic
cellular
compon
simultan
evalu
efficaci
treat
compon
studi
includ
recoveri
surviv
reinfus
label
cell
evalu
clinic
end
point
effect
bleed
platelet
oxygen
deliveri
rbc
current
limit
process
ideal
pi
process
high
effect
wide
rang
pathogen
maintain
biolog
activ
compon
produc
minim
level
reactiv
oxygen
speci
nontox
nonmutagen
noncarcinogen
howev
current
univers
inactiv
agent
abl
elimin
pathogen
therefor
benefit
pi
elimin
reduct
mani
bloodborn
pathogen
possibl
addit
note
among
current
pi
technolog
clear
limit
exampl
effect
spore
accumul
endotoxin
none
shown
inactiv
prion
gener
risk
perspect
riskbenefit
perspect
blood
blood
compon
produc
distribut
canada
develop
countri
extraordinarili
safe
therefor
reason
consid
whether
introduct
pi
would
add
anoth
necessari
layer
safeti
cost
risk
similarli
given
current
low
risk
blood
product
one
must
consid
toler
riskbenefit
profil
pi
might
screen
test
phaseout
replac
introduct
pi
immedi
replac
need
screen
test
time
result
obtain
extens
field
trial
pi
technolog
one
confid
seriou
effect
secondari
introduct
technolog
import
determin
longterm
toxic
absenc
lowfrequ
seriou
effect
must
stress
need
public
consult
unlik
tradit
individu
inform
consent
trial
new
drug
widespread
introduct
pi
requir
broader
inform
consent
public
also
term
societ
inform
consent
type
extens
postmarket
field
trial
would
need
introduct
type
technolog
current
unclear
best
mechan
determin
societ
accept
risksbenefit
pi
technolog
date
health
canada
issu
notic
complianc
approv
issu
drug
webert
et
al
identif
number
sdtreat
plasma
use
canada
howev
submiss
pi
technolog
part
establish
licens
requir
blood
establish
essenti
equival
biolog
licens
applic
bla
unit
state
howev
anticip
futur
request
canadian
feder
govern
initi
sever
action
format
intern
work
group
consid
uniqu
scientif
medic
ethic
regulatori
issu
pi
consult
health
canada
expert
advisori
committe
blood
regul
april
share
inform
concern
pi
stakehold
meet
mark
decreas
risk
transmiss
viral
agent
transfus
past
year
result
improv
donor
select
advanc
laboratori
screen
improv
use
allogen
blood
compon
advanc
blood
compon
manufactur
howev
recent
risk
transmiss
bacteria
parasit
transfus
remain
essenti
unchang
recent
concern
blood
safeti
also
includ
prion
transmiss
noninfecti
risk
residu
risk
transfus
given
threat
rel
straightforward
concept
extrem
difficult
measur
preand
postintervent
risk
surveil
sensit
intervent
efficaci
critic
factor
accur
measur
residu
risk
one
simpli
measur
risk
given
intervent
determin
benefit
intervent
one
must
know
preintervent
risk
postintervent
risk
sensit
measur
assess
risk
pathogen
one
must
consid
plausibl
transmiss
transfus
likelihood
exposur
avail
effect
screen
test
potenti
clinic
signific
diseas
transfus
recipi
american
associ
blood
bank
aabb
introduc
new
standard
mandat
procedur
limit
detect
bacteri
contamin
platelet
compon
place
aabbaccredit
facil
march
perform
activ
surveil
crucial
assess
success
intervent
passiv
surveil
method
may
underst
risk
time
compar
activ
surveil
method
case
effort
mitig
bacteri
risk
lack
activ
surveil
data
made
exceedingli
difficult
assess
success
intervent
situat
compound
differ
process
use
platelet
collect
process
multipl
potenti
sourc
bacteri
contamin
blood
product
wide
variat
estim
preintervent
risk
exist
like
result
differ
surveil
intens
caveat
appli
postintervent
risk
estim
although
countri
activ
hemovigil
system
better
abl
make
assess
enhanc
surveil
mechan
robust
advers
event
definit
estim
falseneg
test
vari
wide
although
base
american
red
cross
data
possibl
determin
approxim
reduct
report
septic
reaction
sepsisrel
fatal
apheresi
platelet
transfus
implement
aabb
standard
parasit
current
constitut
signific
larg
underrecogn
infecti
diseas
risk
associ
transfus
although
recent
step
taken
interven
particular
agent
babesia
speci
cruzi
agent
chaga
diseas
emerg
signific
threat
immigr
pattern
unit
state
elsewher
preintervent
risk
unknown
agent
lack
adequ
surveil
taken
perspect
howev
infecti
risk
transfus
uncommon
perhap
noninfecti
risk
focu
futur
intervent
relat
transfus
safeti
also
appreci
even
safeti
intervent
result
advers
event
illustr
red
eye
syndrom
back
pain
syndrom
associ
leukoreduc
blood
compon
respect
white
particul
matter
observ
blood
product
although
associ
increas
incid
report
advers
reaction
patient
provid
remind
phenomena
unknown
signific
occur
need
surveil
determin
impact
recipi
health
activ
surveil
essenti
provid
object
data
impact
new
technolog
patient
also
help
guid
action
regulatori
bodi
therefor
need
good
surveil
method
determin
impact
new
technolog
health
recipi
one
must
weigh
effect
intervent
potenti
toxic
mitig
risk
even
risk
implement
intervent
thought
zero
greatest
postimplement
risk
may
relat
uncertainti
inher
design
new
technolog
without
effect
system
evalu
efficaci
situat
benefit
unknown
focu
outcom
may
optim
approach
evalu
overal
benefit
new
technolog
transfus
broader
approach
costli
summari
infecti
noninfecti
risk
blood
suppli
remain
despit
implement
pi
technolog
futur
regardless
measur
put
place
improv
blood
safeti
continu
need
assess
residu
risk
evalu
efficaci
intervent
well
expect
unanticip
toxic
monitor
donor
recipi
health
outcom
like
layer
approach
intervent
effect
address
futur
residu
risk
transfus
econom
pi
technolog
pose
complex
question
health
care
system
evid
indic
potenti
pi
substanti
decreas
risk
infecti
noninfecti
transfus
threat
mount
incorpor
multipl
line
evid
model
use
assess
cost
potenti
benefit
recent
occur
although
pi
may
broadrang
capabl
reduc
transfus
threat
econom
perspect
technolog
expens
two
review
articl
sought
assess
econom
evid
variou
transfus
medicin
intervent
highlight
blood
safeti
intervent
conform
standard
notion
cost
effect
reduct
infecti
transfus
risk
adopt
addit
test
nat
hiv
hcv
bacteri
cultur
platelet
mani
set
unlik
pi
technolog
classifi
cost
effect
judg
tradit
threshold
per
qali
save
howev
given
context
blood
safeti
expect
robust
capabl
pi
tradit
costeffect
threshold
may
relev
threshold
typic
appli
specif
intervent
oppos
intervent
broadspectrum
capabl
furthermor
preced
set
blood
safeti
intervent
cost
well
million
per
qali
candid
adopt
pathogen
inactiv
term
sever
differ
technolog
process
effect
differ
blood
compon
technolog
publish
studi
provid
insight
cost
effect
peerreview
publish
evid
sd
ffp
highlight
challeng
conduct
meaning
econom
analys
pi
public
estim
cost
effect
us
per
qali
updat
analysi
use
recent
estim
risk
transmiss
hiv
hcv
hbv
coupl
estim
cost
technolog
gener
result
million
per
qali
us
set
studi
spain
evalu
similar
sd
technolog
cost
effect
us
million
per
qali
studi
focus
risk
transmit
viral
infect
without
sd
treatment
howev
recent
studi
unit
kingdom
includ
noninfecti
threat
trali
assumpt
sd
treatment
compon
manufactur
process
reduc
risk
trali
cost
effect
sd
ffp
improv
per
qali
us
per
qali
psoralen
light
treatment
intercept
singledonor
apheresi
ap
randomdonor
rd
platelet
largest
bodi
avail
econom
evid
analysi
conduct
us
set
predat
current
bacteri
cultur
result
report
differ
patient
group
pediatr
acut
lymphocyt
leukemia
hip
webert
et
al
arthroplasti
coronari
arteri
bypass
graft
adult
nonhodgkin
lymphoma
without
bacteri
cultur
depend
patient
popul
baselin
result
rang
us
million
million
per
qali
bacteri
cultur
us
million
million
per
qali
without
bacteri
cultur
ap
platelet
limit
evid
gener
costeffect
studi
futur
analys
need
take
factor
consider
studi
compar
technolog
intervent
place
given
set
studi
base
infecti
threat
reduc
inactiv
technolog
includ
analys
known
emerg
agent
chikungunya
viru
reunion
island
oppos
unknown
emerg
agent
noninfecti
threat
may
hold
potenti
incorpor
econom
analys
clear
evid
effect
pi
reduc
threat
first
need
establish
measur
increas
product
use
result
loss
compon
therapeut
activ
pi
also
need
consid
greatest
potenti
improv
cost
effect
pi
come
possibl
sever
current
intervent
bacteri
cultur
test
wnv
could
potenti
discontinu
implement
individu
donat
test
nat
hiv
hcv
hbv
wnv
avoid
along
avoid
implement
addit
assay
emerg
virus
eg
dengu
chikungunya
parasit
eg
cruzi
malaria
leishmania
perhap
even
donor
select
criteria
complex
costli
could
modifi
potenti
broadspectrum
coverag
multipl
infecti
noninfecti
threat
use
pi
requir
care
account
event
avert
use
technolog
health
care
cost
prevent
given
broad
rang
potenti
benefit
futur
studi
seek
estim
cost
effect
specif
pi
technolog
requir
use
advanc
method
account
uncertainti
probabilist
sensit
analysi
newer
pi
technolog
adopt
cost
blood
compon
increas
question
technolog
pose
health
care
sector
countri
whether
increas
blood
cost
come
improv
transfus
safeti
potenti
reduc
health
care
expenditur
result
avert
advers
transfus
event
modifi
donor
select
criteria
laboratori
screen
intervent
present
provid
overview
select
develop
pi
technolog
address
present
discuss
futur
direct
pi
technolog
cryofacet
technolog
cryofacet
inc
durham
nc
develop
differ
techniqu
pi
plasma
platelet
rbc
plasma
infecti
agent
inactiv
use
process
consist
germicid
uvb
follow
ozon
prevent
undesir
photooxid
plasma
protein
uvb
light
sensit
plasma
first
deoxygen
use
ultrasound
technolog
treatment
steril
unit
fraction
accord
molecular
weight
albumin
albumin
albumin
fraction
concentr
freez
use
ultrason
assist
technolog
current
develop
data
mainten
coagul
factor
activ
level
yet
avail
cryofacet
rbc
platelet
technolog
reli
use
plan
new
design
counterflow
elutri
remov
infecti
agent
plasma
follow
subsequ
ozon
result
cell
suspens
platelet
store
pathogenreduc
plasma
fraction
lower
molecular
weight
infus
platelet
wash
suspend
degass
salin
treat
germicid
uv
studi
look
vitro
vivo
platelet
rbc
activ
report
interest
given
high
degre
manipul
product
involv
sanquin
technolog
sanquin
intern
limit
amsterdam
netherland
investig
use
light
plasma
inactiv
later
platelet
inactiv
earli
work
focus
use
highintens
broadspectrum
light
puls
platelet
suspend
plasma
inactiv
viru
demonstr
mainten
vitro
platelet
properti
storag
compani
develop
technolog
subsequ
studi
treat
platelet
suspend
plasma
addit
solut
uvc
light
although
number
pathogen
inactiv
log
treatment
activ
platelet
fibrinogen
receptor
glycoprotein
iibiiia
caus
platelet
aggreg
result
decreas
platelet
count
also
note
hiv
rel
insensit
activ
uvc
treatment
current
sanquin
involv
clinic
trial
compar
platelet
untreat
platelet
store
platelet
addit
solut
iii
sanquin
intern
limit
studi
inactiv
pathogen
rbc
use
posit
charg
porphryin
compound
one
compound
monophenyltri
porphyrin
chlorid
yield
least
hemolysi
abl
inactiv
model
singlestrand
rna
viru
vesicular
stomat
viru
vsv
log
howev
agent
includ
intracellular
hiv
requir
prolong
illumin
inactiv
result
unaccept
hemolysi
hemolysi
treatment
rbc
suspens
problem
hemolysi
virucid
photoinactiv
rbc
suspens
use
agent
common
theme
report
sever
laboratori
theoret
may
minim
use
dye
mb
dimethylen
blue
bind
strongli
nucleic
acid
provid
basi
specif
pathogen
unlik
rbc
contain
genom
nucleic
acid
hemolysi
upon
illumin
compound
may
occur
sever
mechan
freeli
float
dye
near
rbc
produc
singlet
oxygen
illumin
result
rbc
damag
mani
nucleic
acid
bind
dye
also
bind
rbc
membran
result
photoinduc
hemolysi
anoth
problem
photosensit
dye
fact
dye
abl
cross
cell
membran
necessari
kill
intracellular
virus
exampl
dye
includ
mb
posit
chang
porphyrin
develop
flexibl
photosensit
gener
photosensit
dye
rigid
planar
aromat
compound
activ
light
whether
free
solut
bound
substrat
howev
structur
sensit
permit
separ
aromat
ring
system
rotat
adjoin
coval
linkag
partial
singlebond
charact
rigidli
bound
substrat
rotat
permit
energi
absorb
light
dissip
heat
bond
rotat
howev
dye
intercal
nucleic
acid
becom
rigid
photosensit
discoveri
flexibl
dye
allow
develop
rbc
cell
inactiv
system
specif
pathogen
caus
excess
rbc
cell
damag
first
exampl
flexibl
photosensit
use
rbc
cell
decontamin
nucleic
acid
stain
dye
thiopyrylium
tp
tp
bound
rbc
cell
addit
nucleic
acid
second
substanc
dipyridamol
commonli
use
vasodil
drug
also
antioxid
may
ad
inhibit
bind
photodamag
rbc
membran
thiopyrylium
phototreat
rbc
suspens
contain
dipyridamol
jcm
red
light
result
robust
inactiv
number
intracellular
extracellular
virus
well
bacteria
parasit
storag
day
rbc
exhibit
accept
level
hemolysi
morpholog
score
extracellular
ph
atp
glucos
use
rate
lactat
product
howev
treat
sampl
exhibit
substanti
increas
potassium
efflux
compar
control
day
atp
level
significantli
differ
control
autolog
infus
fresh
tpphototr
canin
rbc
cell
result
compar
recoveri
surviv
untreat
fresh
canin
rbc
one
disadvantag
tp
system
requir
presenc
second
drug
dipyridamol
limit
rbc
photodamag
commerci
develop
system
would
requir
toxicolog
investig
tp
dipyridamol
well
combin
drug
would
like
make
difficult
get
system
approv
regulatori
agenc
identif
flexibl
dye
bind
poorli
rbc
may
make
addit
competit
inhibitor
unnecessari
one
dye
thiazol
orang
nucleic
acidintercal
dye
use
stain
identifi
reticulocyt
malariainfect
rbc
show
promis
photosensit
rbc
decontamin
without
need
second
drug
thiazol
orang
bind
rbc
less
tp
treatment
rbc
suspens
thiazol
orang
jcm
cool
white
light
also
result
robust
inactiv
intracellular
extracellular
virus
log
bacteria
photoinactiv
thiazol
orang
differ
extent
depend
speci
least
log
speci
log
bacteria
inactiv
discuss
open
question
util
emerg
technolog
pi
prevent
transfusionrel
infect
develop
world
acknowledg
pi
technolog
present
form
expens
could
implement
mani
less
develop
region
world
time
optim
howev
refin
pi
technolog
could
eventu
major
impact
prevent
transfusiontransmiss
infect
less
financi
capabl
nation
seen
signific
impetu
continu
need
develop
pi
technolog
addit
point
made
like
feasibl
continu
introduc
addit
test
everi
emerg
pathogen
finit
resourc
avail
ensur
transfus
safeti
preclud
approach
cost
introduc
addit
test
emerg
pathogen
would
consider
suggest
costeffect
model
would
invalu
assess
impact
new
technolog
context
resourc
avail
particularli
disadvantag
countri
main
benefit
pi
technolog
identifi
reduct
total
elimin
risk
transfusiontransmit
bacteri
sepsi
b
minim
alreadi
extrem
low
risk
viral
transmiss
c
addit
protect
cellassoci
virus
cmv
probabl
elimin
transfusionassoci
gvhd
e
possibl
attenu
immunomodulatori
effect
transfus
note
risk
transmiss
hiv
hcv
hbv
alreadi
extrem
low
sensit
viral
screen
assay
current
place
canada
residu
risk
acquir
hiv
infect
transfus
approxim
per
million
blood
donat
infect
per
year
figur
similar
hcv
residu
risk
hbv
remain
common
viral
hepat
transmit
transfus
per
approxim
case
per
year
canada
point
current
approach
screen
blood
suppli
prevent
viral
hepat
hiv
reduc
risk
extrem
low
level
howev
risk
associ
unknown
pathogen
remain
suggest
pathogen
appear
emerg
increas
frequenc
statement
disput
emerg
pathogen
alway
present
although
necessarili
found
relev
blood
transfus
recipi
note
biolog
fluid
medic
given
intraven
administr
blood
product
steril
endotoxinfre
ideal
safeti
blood
compon
match
fraction
protein
product
current
low
risk
diseas
transmiss
due
use
robust
viral
inactiv
step
built
manufactur
process
one
particip
felt
essenti
countri
introduc
pi
technolog
activ
surveil
system
place
pi
implement
note
benefit
margin
safeti
pi
product
may
differ
differ
patient
group
exampl
risk
associ
transfus
pi
product
may
higher
neonat
popul
adult
higher
life
expect
consider
may
therefor
necessit
mainten
multipl
inventori
variou
blood
compon
point
despit
use
pi
product
may
possibl
elimin
requir
bacteri
screen
blood
product
particularli
platelet
although
pi
appear
effect
reduc
risk
transfusiontransmit
sepsi
bacteri
screen
techniqu
much
effect
yet
uncertain
current
estim
suggest
bacteri
contamin
product
detect
avail
screen
method
wherea
pi
may
reduc
risk
close
exampl
must
recogn
pi
fail
elimin
bacteri
spore
report
norway
use
sdtreat
plasma
routin
sinc
intervent
elimin
occurr
trali
like
relat
dilut
hla
antibodi
sd
plasma
pool
use
sd
plasma
also
appear
associ
decreas
incid
allerg
reaction
also
point
current
test
avail
screen
prionassoci
diseas
pi
appear
ineffect
agent
therefor
implement
pi
technolog
would
mitig
risk
associ
agent
need
continu
effort
screen
blood
suppli
remov
pathogen
would
thu
remain
issu
whether
emerg
hbv
follow
hiv
hcv
could
serv
basi
public
health
agenc
model
risk
emerg
pathogen
health
care
economist
consensu
panel
advis
model
situat
best
work
concret
clearli
defin
emerg
agent
suggest
dengu
viru
could
serv
use
prototyp
regard
point
health
polici
agenc
respons
develop
valid
model
assess
cost
effect
variou
intervent
address
emerg
threat
public
safeti
import
hemovigil
system
place
mani
countri
emphas
detect
emerg
new
pathogen
also
monitor
potenti
toxic
new
therapeut
intervent
note
mani
emerg
microbiologicalrel
ill
caus
zoonot
agent
may
difficult
justifi
expenditur
measur
prevent
spread
agent
transfus
diseas
endem
particular
commun
effect
transmiss
mean
burden
ill
commun
must
consid
alloc
resourc
widespread
implement
pi
technolog
would
consider
chang
natur
blood
product
know
today
thu
suggest
pi
therefor
pursu
without
adequ
public
consult
well
introduct
activ
surveil
latter
must
involv
followup
larg
cohort
transfus
recipi
mani
surveil
system
current
place
voluntari
passiv
approach
surveil
potenti
complic
aris
webert
et
al
widespread
introduct
pi
technolog
must
activ
must
also
regulatori
oversight
addit
surveil
must
long
term
follow
recipi
mani
year
consider
discuss
around
level
inform
consent
necessari
postmarket
surveil
point
preced
exist
countri
canada
activ
surveil
sever
advers
reaction
vaccin
carri
without
requir
specif
inform
consent
anoth
ethic
consider
rais
concern
approach
taken
event
univers
implement
pi
technolog
feasibl
ideal
univers
approach
implement
pi
pursu
howev
limit
current
propos
pi
technolog
univers
approach
pi
blood
compon
would
probabl
possibl
time
exampl
obstacl
pi
rbc
remain
substanti
circumst
implement
pi
technolog
would
like
result
level
safeti
differ
blood
compon
attend
need
continu
perform
microbiolog
screen
rbc
compon
univers
implement
pi
blood
compon
possibl
ethic
consider
select
implement
pi
technolog
would
address
includ
issu
relat
vari
level
safeti
blood
product
need
explicit
inform
consent
patient
receiv
pi
product
exampl
would
appropri
offer
pitreat
product
pediatr
popul
exclus
similar
approach
taken
unit
kingdom
transfus
mbtreat
plasma
person
younger
year
similar
concern
could
aris
crossov
exist
inventori
pi
inventori
moreov
signific
differ
known
exist
pi
nonpi
product
could
becom
import
element
inform
consent
transfus
also
point
polici
maker
must
retain
flexibl
make
decis
respect
appropri
alloc
limit
resourc
univers
approach
pi
attain
characterist
pi
product
vari
consider
depend
process
manufactur
solventdeterg
plasma
one
manufactur
could
differ
biochem
anoth
manufactur
sd
plasma
product
differ
relat
process
paramet
hold
time
extract
differ
chemic
andor
enzym
use
extract
process
one
therefor
assum
sdprocess
plasma
product
equival
henc
need
clinic
trial
activ
surveil
time
assess
properti
potenti
complic
product
therefor
suggest
manufactur
encourag
work
togeth
effort
standard
process
avail
product
compar
repres
us
fda
indic
fda
would
posit
ensur
effect
postmarket
surveil
perceiv
safeti
issu
may
exist
health
canada
concur
european
regul
acknowledg
howev
oversight
might
logist
difficult
mani
differ
pi
technolog
current
develop
andor
like
develop
forese
futur
note
adequ
power
random
clinic
trial
assess
viral
remov
would
financi
prohibit
mani
measur
current
place
reduc
risk
viral
transmiss
transfus
low
level
howev
clinic
trial
essenti
assess
clinic
effect
variou
pitreat
product
suggest
pi
place
cost
save
could
realiz
probabl
reason
continu
perform
bacteri
screen
addit
donor
questionnair
could
modifi
wnv
antihepat
b
core
test
would
becom
redund
screen
syphili
would
longer
requir
consider
skeptic
whether
cost
save
would
actual
realiz
regulatori
constraint
would
like
permit
discontinu
exist
donor
screen
practic
consid
unlik
discontinu
hiv
hcv
hbv
test
would
accept
base
polit
consider
societ
pressur
would
thu
take
mani
year
pi
technolog
valid
proceed
consensu
confer
allow
discontinu
variou
microbiolog
screen
test
similar
situat
cmv
serolog
test
implement
univers
leukoreduct
consid
unlik
physician
would
accept
discontinu
establish
screen
practic
includ
irradi
blood
product
transplant
patient
despit
appar
like
effect
pi
prevent
gvhd
point
countri
canada
provid
univers
leukoreduc
product
addit
perform
cmv
serolog
test
specif
indic
would
like
benefit
pi
reduct
cmv
test
acknowledg
costsav
measur
implement
pi
may
vari
countri
countri
depend
exist
practic
well
regulatori
environ
opportun
cost
relat
pi
discuss
state
problem
one
limit
resourc
rather
concept
resourc
avail
exampl
cost
increment
associ
use
posit
identif
system
prevent
one
common
caus
transfusionrel
mortal
modest
compar
mani
cost
associ
collect
process
administr
microbiolog
safe
blood
product
point
sever
countri
europ
implement
pi
routin
platelet
product
observ
reduc
product
loss
process
platelet
outdat
alsac
franc
exampl
approach
contrast
platelet
outdat
level
much
higher
center
attribut
stabil
suppli
shortliv
product
note
high
blood
donor
loss
inher
current
approach
transmiss
diseas
test
donat
includ
econom
analysi
abil
retain
donor
would
signific
maintain
adequaci
blood
suppli
would
impact
donor
recruit
strategi
exampl
montreal
quebec
collect
roughli
donat
per
year
sinc
approxim
donor
exclud
donor
registri
basi
transmiss
diseas
test
test
current
use
screen
blood
donat
falseposit
rate
order
per
donat
donor
reinstat
protocol
wide
avail
even
reinstat
protocol
experi
shown
minor
donor
return
donor
pool
econom
analysi
inform
decis
relat
implement
new
technolog
costconsequ
analysi
would
optim
analysi
take
consider
context
decis
costeffect
analysi
hand
determin
benefit
number
qali
save
without
regard
context
intervent
benefit
number
qali
save
may
entir
differ
valu
differ
countri
depend
context
decis
therefor
suggest
costconsequ
analysi
would
prefer
approach
assess
potenti
valu
new
technolog
consider
concern
express
potenti
inabl
blood
regulatori
agenc
allow
pi
process
move
forward
exampl
ask
amount
data
requir
allow
regul
make
decis
strong
percept
current
regul
inhibit
abil
implement
chang
histori
show
regul
find
difficult
discontinu
certain
transmiss
diseas
test
even
risk
shown
longer
exist
exampl
blood
product
advisori
committe
unit
state
recommend
discontinu
syphili
test
blood
suppli
mani
year
ago
yet
test
continu
perform
blood
donat
unit
state
suggest
requir
test
new
technolog
becom
detail
counterproduct
ration
assess
new
approach
transfus
safeti
recommend
regul
clearli
defin
data
might
requir
licensur
new
technolog
past
manufactur
requir
develop
concept
move
regulatori
process
bring
new
technolog
market
felt
timeconsum
labori
approach
becom
cost
prohibit
base
sophist
newer
technolog
develop
felt
role
blood
oper
facilit
process
must
also
clarifi
cooper
effort
innov
new
technolog
regul
blood
oper
implement
new
technolog
final
suggest
regul
need
commun
effect
among
effort
achiev
intern
harmon
approach
use
assess
accept
new
technolog
univers
applic
regul
need
togeth
decisionmak
process
must
capabl
quickli
address
new
pathogen
threat
may
emerg
futur
observ
major
chang
think
transfus
safeti
sinc
emerg
hiv
pandem
earli
suggest
pi
repres
new
paradigm
shift
move
focu
away
reactiv
develop
new
test
method
elimin
microbiolog
threat
preemptiv
think
blood
safeti
dr
blajchman
hamilton
ontario
refer
work
thoma
kuhn
philosopherscientist
massachusett
institut
technolog
cambridg
note
major
chang
scienc
repres
paradigm
shift
kuhn
note
major
conflict
often
occur
support
old
paradigm
confront
new
paradigm
new
way
think
intern
transfus
commun
find
today
old
paradigm
tend
reactiv
test
new
microbiolog
threat
appear
felt
transfus
medicin
commun
need
move
forward
think
new
paradigm
preemptiv
implement
new
approach
toward
improv
microbiolog
safeti
use
global
approach
high
likelihood
deal
emerg
pathogen
thu
decis
respect
introduct
pi
technolog
must
base
assess
benefit
risk
separ
safetyqu
care
econom
aspect
decisionmak
process
may
essenti
effort
therefor
made
transfus
medicin
commun
support
manufactur
evalu
risk
benefit
new
technolog
target
research
initi
assist
regul
assess
approv
new
approach
blood
safeti
transfus
medicin
commun
need
take
respons
process
ensur
realiz
potenti
preemptiv
new
paradigm
deal
microbiolog
blood
safeti
